Raphael Koch, Lianne Haveman, Ruth Ladenstein, Benedicte Brichard, Heribert Jürgens, Sona Cyprova, Henk van den Berg, Wolf Hassenpflug, Anna Raciborska, Torben Ek, Daniel Baumhoer, Gerlinde Egerer, Leo Kager, Marleen Renard, Peter Hauser, Stefan Burdach, Judith V M G Bovee, Angela M Hong, Peter Reichardt, Jarmila Kruseova, Arne Streitbürger, Thomas Kühne, Torsten Kessler, Marie Bernkopf, Trude Butterfaß-Bahloul, Catharina Dhooge, Sebastian Bauer, János Kiss, Michael Paulussen, Fiona Bonar, Andreas Ranft, Beate Timmermann, Jelena Rascon, Volker Vieth, Jukka Kanerva, Andreas Faldum, Wolfgang Hartmann, Lars Hjorth, Vivek A Bhadri, Markus Metzler, Hans Gelderblom, Uta Dirksen
PURPOSE: The phase III, open-label, prospective, multicenter, randomized Ewing 2008R1 trial (EudraCT2008-003658-13) was conducted in 12 countries to evaluate the effect of zoledronic acid (ZOL) maintenance therapy compared with no add-on regarding event-free survival (EFS, primary endpoint) and overall survival (OS) in standard-risk Ewing sarcoma (EWS). PATIENTS AND METHODS: Eligible patients had localized EWS with either good histologic response to induction chemotherapy and/or small tumors (<200 mL)...
December 15, 2023: Clinical Cancer Research